U-46619 manufacturers
- U-46619
-
- $243.00 / 1mg
-
2024-11-19
- CAS:56985-40-1
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | U-46619 Basic information |
| Product Name: | U-46619 | | Synonyms: | 9,11-DIDEOXY-11ALPHA,9ALPHA-EPOXYMETHANO;9,11-DIDEOXY-11A,9A-EPOXYMETHANO-*PROSTA GLANDIN F2A;9,11-dideoxy-11α,9α-epoxymethanoprostaglandin f2α;9,11-dideoxy-11alpha,9alpha-epoxymethanoprostaglandin F2a;(5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-Hydroxy-1-octenyl]-2 -oxabicyclo[2.2.1]hept-5-yl]-5-heptenoic acid;(5Z)-7-[(1R,4S)-6β-[(1E,3S)-3-Hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]heptan-5α-yl]-5-heptenoic acid;(Z)-7-[(1R,4S)-6β-[(E,S)-3-Hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]hept-5α-yl]-5-heptenoic acid;11α,9α-Epoxymethanoprostaglandin H2 | | CAS: | 56985-40-1 | | MF: | C21H34O4 | | MW: | 350.49 | | EINECS: | | | Product Categories: | Prostanoid receptor and related | | Mol File: | 56985-40-1.mol |  |
| | U-46619 Chemical Properties |
| Boiling point | 519.7±30.0 °C(Predicted) | | density | 1.092±0.06 g/cm3(Predicted) | | Fp | -10 °C | | storage temp. | -20°C | | solubility | ≥100 mg/mL in DMSO, ≥100 mg/mL in Ethanol, ≥100 mg/mL in DMF, ≥2 mg/mL in PBS pH 7.2 | | pka | 4.76±0.10(Predicted) | | form | solution | | color | Colorless to light yellow | | BRN | 4267334 |
| Hazard Codes | F,Xi | | Risk Statements | 11-36-66-67 | | Safety Statements | 16-26 | | RIDADR | UN 1231 3/PG 2 | | WGK Germany | 2 | | RTECS | MJ9681090 | | F | 8-10-23 | | Toxicity | LD50 intravenous in mouse: 66ug/kg |
| | U-46619 Usage And Synthesis |
| Uses | U 46619 is a PGH2 analog that may be used as a thromboxane A2 (TP) receptor agonist affecting mitogenic growth of vascular smooth muscle in humans. | | Biological Activity | PGH 2 (TXA 2 ) analog that is a potent and stable thromboxane A 2 (TP) receptor agonist (EC 50 = 0.035 μ M). Potently stimulates TP receptor-mediated, but not other prostaglandin receptor-mediated responses in various in vitro preparations. Activates ERK-1 and ERK-2 in HEK-293 cells expressing TP α and TP β receptors. | | Biochem/physiol Actions | Thromboxane receptor agonist. | | in vitro | u46619 showed a biphasic effect on human platelets. shape change and mlcp occurred at low concentrations of this compound (ec50 = 0.035 um and 0.057 um), whereas serotonin release, platelet at higher concentrations (ec50 = 0.536 um and 1.31 um). the effect on platelet shape change and mlcp is receptor mediated [3]. | | in vivo | u46619, through activation of eta and etb receptors, elicits renal cortical vasoconstriction and medullary vasodilation in the rat [2]. in conscious shr (spontaneously hypertensive rats), 1-100 nmol/kg u-46619 (i.c.v.) induced a dose-related increase in blood pressure but had no significant effect on heart rate [1]. | | storage | Store at -20°C | | references | [1] sirén al, svartstrm-fraser m, paakkari i. central cardiovascular effects of the endoperoxide analogue u-46619 in rats. prostaglandins leukot med. 1985 mar; 17 (3): 381-6.
[2] hantz h, adesuyi a, adebayo o. differential effects of u46619 on renal regional hemodynamics in the rat: involvement of endothelin. j pharmacol exp ther. 2001 oct; 299 (1): 372-6.
[3] morinelli ta1, niewiarowski s, daniel jl, smith jb. receptor-mediated effects of a pgh2 analogue (u 46619) on human platelets. am j physiol. 1987 nov; 253 (5 pt 2): h1035-43. |
| | U-46619 Preparation Products And Raw materials |
|